Alzheimer's disease: Recent treatment strategies

M Vaz, S Silvestre - European journal of pharmacology, 2020 - Elsevier
Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

Tau-targeting therapies for Alzheimer disease

EE Congdon, EM Sigurdsson - Nature Reviews Neurology, 2018 - nature.com
Alzheimer disease (AD) is the most common form of dementia. Pathologically, AD is
characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated …

[HTML][HTML] Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease

SP Yu, MQ Jiang, SS Shim, S Pourkhodadad… - Molecular …, 2023 - Springer
Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the
comorbidity of these brain disorders in aging individuals represents a significant challenge …

The inositol trisphosphate/calcium signaling pathway in health and disease

MJ Berridge - Physiological reviews, 2016 - journals.physiology.org
Many cellular functions are regulated by calcium (Ca2+) signals that are generated by
different signaling pathways. One of these is the inositol 1, 4, 5-trisphosphate/calcium …

[HTML][HTML] Type 2 diabetes mellitus and Alzheimer's disease: shared molecular mechanisms and potential common therapeutic targets

R Hamzé, E Delangre, S Tolu, M Moreau… - International journal of …, 2022 - mdpi.com
The global prevalence of diabetes mellitus and Alzheimer's disease is increasing alarmingly
with the aging of the population. Numerous epidemiological data suggest that there is a …

Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014

LS Schneider, F Mangialasche… - Journal of internal …, 2014 - Wiley Online Library
The modern era of drug development for A lzheimer's disease began with the proposal of
the cholinergic hypothesis of memory impairment and the 1984 research criteria for A …

[HTML][HTML] GSK-3β, a pivotal kinase in Alzheimer disease

M Llorens-Marítin, J Jurado, F Hernández… - Frontiers in molecular …, 2014 - frontiersin.org
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of
AD is considered to be multifactorial as only a negligible percentage of cases have a familial …

Current and future treatments for Alzheimer's disease

KG Yiannopoulou… - Therapeutic advances in …, 2013 - journals.sagepub.com
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important
medical and social problems in older people in industrialized and non-industrialized …

[HTML][HTML] The importance of tau phosphorylation for neurodegenerative diseases

W Noble, DP Hanger, CCJ Miller… - Frontiers in neurology, 2013 - frontiersin.org
Fibrillar deposits of highly phosphorylated tau are a key pathological feature of several
neurodegenerative tauopathies including Alzheimer's disease (AD) and some …

[HTML][HTML] Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical …

N Basheer, T Smolek, I Hassan, F Liu, K Iqbal… - Molecular …, 2023 - nature.com
Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets
in current pharmacological research, with indications ranging from oncology to …